Does IVIg administration yield improved immune function in very premature neonates

Journal of Perinatology

Volumn 30, Issue 10, 2010, Pages 635-642

  Wynn, J L ^a   Seed, P C ^a   Cotten, C M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

immune function; IVIg; neonate; premature; sepsis

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; GESTATIONAL AGE; HOSPITAL INFECTION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; NEWBORN SEPSIS; PREMATURITY; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PHAGOCYTOSIS; SEPSIS;

EID: 77957585989     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2009.197     Document Type: Review

References (70)

1. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute Of Child Health And Human Development Neonatal Research Network. N Engl J Med 1994; 330: 1107-1113.
2. Christensen RD, Hardman T, Thornton J, Hill HR. A randomized, double-blind, placebo-controlled investigation of the safety of intravenous immune globulin administration to preterm neonates. J Perinatol 1989; 9: 126-130.
3. Kempf C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2007; 35: 35-42.
4. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD neonatal research network. Semin Perinatol. 2003; 27: 293-301.
5. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 2006; 19: 290-297.
6. Wilson-Costello D, Friedman H, Minich N, Siner B, Taylor G, Schluchter M et al. Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000-2002. Pediatrics 2007; 119: 37-45.
7. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2004. Issue no.1. Article no. CD001239.
8. The INIS Study. International neonatal immunotherapy study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis - an international, placebo controlled, multicentre randomised trial. BMC Pregnancy Childbirth 2008; 8: 52.
9. Strand M, Jobe AH. The multiple negative randomized controlled trials in perinatology - why? Semin Perinatol 2003; 27: 343-350.
10. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev 2004. Issue no. 1. Article no. CD000361.
11. Shah PS, Kaufman DA. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst Rev 2009. Issue no. 2. Article no. CD006449.
12. Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009; 53: 2879-2886.
13. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27: 233-245.
14. Mussi-Pinhata MM, Rego MA. Immunological peculiarities of extremely preterm infants: a challenge for the prevention of nosocomial sepsis. J Pediatr (Rio J) 2005; 81: S59-S68.
15. Kallman J, Schollin J, Schalen C, Erlandsson A, Kihlstrom E. Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates. Arch Dis Child Fetal Neonatal Ed 1998; 78: F46-F50.
16. Wolach B, Dolfin T, Regev R, Gilboa S, Schlesinger M. The development of the complement system after 28 weeks' gestation. Acta Paediatr 1997; 86: 523-527.
17. Cates KL, Goetz C, Rosenberg N, Pantschenko A, Rowe JC, Ballow M. Longitudinal development of specific and functional antibody in very low birth weight premature infants. Pediatr Res 1988; 23: 14-22.
18. Lewis D, Wilson C. Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection. In: Remington, Klein, Wilson and Baker (eds.) Infectious Diseases of the Fetus and Newborn Infant. 6th edn Elsevier Saunders: Philadelphia, 2006.
19. Baley JE. Neonatal sepsis: the potential for immunotherapy. Clin Perinatol 1988; 15: 755-771.
20. Shaw CK, Thapalial A, Shaw P, Malla K. Intravenous immunoglobulins and haematopoietic growth factors in the prevention and treatment of neonatal sepsis: ground reality or glorified myths? Int J Clin Pract 2007; 61: 482-487.
21. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608-615.
22. Maeda M, van Schie RC, Yuksel B, Greenough A, Fanger MW, Guyre PM et al. Differential expression of Fc receptors for IgG by monocytes and granulocytes from neonates and adults. Clin Exp Immunol 1996; 103: 343-347.
23. Henneke P, Berner R. Interaction of neonatal phagocytes with group B streptococcus: recognition and response. Infect Immun 2006; 74: 3085-3095.
24. Payne NR, Fleit HB. Extremely low birth weight infants have lower Fc gamma RIII (CD 16) plasma levels and their PMN produce less Fc gamma RIII compared to adults. Biol Neonate 1996; 69: 235-242.
25. Fjaertoft G, Hakansson L, Foucard T, Ewald U, Venge P. CD64 (Fcgamma receptor I) cell surface expression on maturing neutrophils from preterm and term newborn infants. Acta Paediatr 2005; 94: 295-302.
26. Carr R, Davies JM. Abnormal FcRIII expression by neutrophils from very preterm neonates. Blood 1990; 76: 607-611.
27. Ng PC, Li K, Wong RP, Chui KM, Wong E, Fok TF. Neutrophil CD64 expression: a sensitive diagnostic marker for late-onset nosocomial infection in very low birthweight infants. Pediatr Res 2002; 51: 296-303.
28. Fairchild KD, Hudson RG, Douglas SD, McKenzie SE, Polin RA. Effect of gamma interferon on expression of Fc gamma receptors in monocytes of newborn infants and adults. Clin Diagn Lab Immunol 1996; 3: 464-469.
29. Danikas DD, Karakantza M, Theodorou GL, Sakellaropoulos GC, Gogos CA. Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. Clin Exp Immunol 2008; 154: 87-97.
30. Givner LB, Edwards MS, Anderson DC, Baker CJ. Immune globulin for intravenous use: enhancement of in vitro opsonophagocytic activity of neonatal serum. J Infect Dis 1985; 151: 217-220.
31. Weisman LE, Cruess DF, Fischer GW. Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr Infect Dis J 1994; 13: 1122-1125.
32. Geelen SP, Fleer A, Bezemer AC, Gerards LJ, Rijkers GT, Verhoef J. Deficiencies in opsonic defense to pneumococci in the human newborn despite adequate levels of complement and specific IgG antibodies. Pediatr Res 1990; 27: 514-518.
33. Peden DB, VanDyke K, Ardekani A, Mullett MD, Myerberg DZ, VanDyke C. Diminished chemiluminescent responses of polymorphonuclear leukocytes in severely and moderately preterm neonates. J Pediatr 1987; 111: 904-906.
34. Bialek R, Bartmann P. Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants? Infection 1998; 26: 375-378.
35. Fujiwara T, Taniuchi S, Hattori K, Kobayashi T, Kinoshita Y, Kobayashi Y. Effect of immunoglobulin therapy on phagocytosis by polymorphonuclear leucocytes in whole blood of neonates. Clin Exp Immunol 1997; 107: 435-439.
36. Schutze GE, Hall MA, Baker CJ, Edwards MS. Role of neutrophil receptors in opsonophagocytosis of coagulase-negative Staphylococci. Infect Immun 1991; 59: 2573-2578.
37. Shaio MF, Yang KD, Bohnsack JF, Hill HR. Effect of immune globulin intravenous on opsonization of bacteria by classic and alternative complement pathways in premature serum. Pediatr Res 1989; 25: 634-640.
38. Fleer A, Gerards LJ, Aerts P, Westerdaal NA, Senders RC, van Dijk H et al. Opsonic defense to Staphylococcus epidermidis in the premature neonate. J Infect Dis 1985; 152: 930-937.
39. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD neonatal research network. Pediatrics 2002; 110: 285-291.
40. Krediet TG, Beurskens FJ, van Dijk H, Gerards LJ, Fleer A. Antibody responses and opsonic activity in sera of preterm neonates with coagulase-negative staphylococcal septicemia and the effect of the administration of fresh frozen plasma. Pediatr Res 1998; 43: 645-651.
41. Lassiter HA, Robinson TW, Brown MS, Hall DC, Hill HR, Christensen RD. Effect of intravenous immunoglobulin G on the deposition of immunoglobulin G and C3 onto type III group B streptococcus and Escherichia coli K1. J Perinatol 1996; 16: 346-351.
42. Lassiter HA, Speranza MJ, Hall RT, Meade V, Christensen RD, Parker CJ. Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin. J Perinatol 1990; 10: 27-31.
43. Correa AG, Baker CJ, Schutze GE, Edwards MS. Immunoglobulin G enhances C3 degradation on coagulase-negative staphylococci. Infect Immun 1994; 62: 2362-2366.
44. Kohl S, Sigouroudinia M, Engleman EG. Adhesion defects of antibody-mediated target cell binding of neonatal natural killer cells. Pediatr Res 1999; 46: 755-759.
45. Frazier JP, Kohl S, Pickering LK, Loo LS. The effect of route of delivery on neonatal natural killer cytotoxicity and antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells. Pediatr Res 1982; 16: 558-560.
46. Hashimoto G, Wright PF, Karzon DT. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect Immun 1983; 42: 214-218.
47. Stiehm ER, Roberts RL, Ank BJ, Plaeger-Marshall S, Salman N, Shen L et al. Comparison of cytotoxic properties of neonatal and adult neutrophils and monocytes and enhancement by cytokines. Clin Diagn Lab Immunol 1994; 1: 342-347.
48. Kohl S, Frazier JP, Pickering LK, Loo LS. Normal function of neonatal polymorphonuclear leukocytes in antibody-dependent cellular-cytotoxicity to herpes simplex virus-infected cells. J Pediatr 1981; 98: 783-785.
49. Nguyen QH, Roberts RL, Ank BJ, Lin SJ, Lau CK, Stiehm ER. Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12. Clin Diagn Lab Immunol 1998; 5: 98-104.
50. Kohl S, Loo LS, Gonik B. Analysis in human neonates of defective antibody-dependent cellular cytotoxicity and natural killer cytotoxicity to herpes simplex virus-infected cells. J Infect Dis 1984; 150: 14-19. (Pubitemid 14093827)
51. Jenkins M, Mills J, Kohl S. Natural killer cytotoxicity and antibody-dependent cellular cytotoxicity of human immunodeficiency virus-infected cells by leukocytes from human neonates and adults. Pediatr Res 1993; 33: 469-474.
52. Shore SL, Milgrom H, Wood PA, Nahmias AJ. Antibody-dependent cellular cytotoxicity to target cells infected with herpes simplex viruses: functional adequacy in the neonate. Pediatrics 1977; 59: 22-28.
53. Merrill JD, Sigaroudinia M, Kohl S. Characterization of natural killer and antibody-dependent cellular cytotoxicity of preterm infants against human immunodeficiency virus-infected cells. Pediatr Res 1996; 40: 498-503. (Pubitemid 26282587)
54. Wright Jr WC, Ank BJ, Herbert J, Stiehm ER. Decreased bactericidal activity of leukocytes of stressed newborn infants. Pediatrics 1975; 56: 579-584.
55. Shigeoka AO, Santos JI, Hill HR. Functional analysis of neutrophil granulocytes from healthy, infected, and stressed neonates. J Pediatr 1979; 95: 454-460.
56. Drossou V, Kanakoudi F, Tzimouli V, Sarafidis K, Taparkou A, Bougiouklis D et al. Impact of prematurity, stress and sepsis on the neutrophil respiratory burst activity of neonates. Biol Neonate 1997; 72: 201-209.
57. Harper TE, Christensen RD, Rothstein G, Hill HR. Effect of intravenous immunoglobulin G on neutrophil kinetics during experimental group B streptococcal infection in neonatal rats. Rev Infect Dis 1986; 8(Suppl 4): S401-S408.
58. Harper TE, Christensen RD, Rothstein G. The effect of administration of immunoglobulin to newborn rats with Escherichia coli sepsis and meningitis. Pediatr Res 1987; 22: 455-460.
59. Christensen RD, Brown MS, Hall DC, Lassiter HA, Hill HR. Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis. J Pediatr 1991; 118: 606-614.
60. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993; 23: 540-545.
61. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62: S12-S18; quiz S19-21.
62. Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett 2007; 581: 2017-2021.
63. Dembinski J, Martini R, Behrendt D, Bartmann P. Modification of cord blood IL-6 production with IgM enriched human immunoglobulin in term and preterm infants. Cytokine 2004; 26: 25-29.
64. Sugita K, Hirao J, Arisaka O, Eguchi M. gamma-Globulin-induced modulation with necrotic-like morphology of peripheral blood neutrophils. Eur J Pharmacol 2005; 513: 141-144.
65. Tarnow-Mordi W, Cust A, Brocklehurst P, Mohan P, Isaacs D. Polyclonal intravenous immunoglobulin to prevent brain injury in preterm infants. Lancet 2002; 359: 1522; author reply 1523-1524..
66. Devlin LA, Lassiter HA. Immunoenhancement to prevent nosocomial coagulase-negative staphylococcal sepsis in very low-birth-weight infants. Clin Perinatol 2004; 31: 69-75.
67. Capparelli EV, Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD et al. Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. Antimicrob Agents Chemother 2005; 49: 4121-4127.
68. Benjamin Jr DK, Schelonka R, White R, Holley Jr HP, Bifano E, Cummings J et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 2006; 26: 290.
69. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 2007; 151: 260-265, 265 e261.
70. Suri M, Harrison L, Van de Ven C, Cairo MS. Immunotherapy in the prophylaxis and treatment of neonatal sepsis. Curr Opin Pediatr 2003; 15: 155-160.